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Abstract
Significance: Reactive oxygen species (ROS) play a critical role in vascular disease. While there are many possible
sources of ROS, nicotinamide adenine dinucleotide phosphate (NADPH) oxidases play a central role. They are a
source of ‘‘kindling radicals,’’ which affect other enzymes, such as nitric oxide synthase endothelial nitric oxide
synthase or xanthine oxidase. This is important, as risk factors for atherosclerosis (hypertension, diabetes,
hypercholesterolemia, and smoking) regulate the expression and activity of NADPH oxidases in the vessel wall.
Recent Advances: There are seven isoforms in mammals: Nox1, Nox2, Nox3, Nox4, Nox5, Duox1 and Duox2.
Nox1, Nox2, Nox4, and Nox5 are expressed in endothelium, vascular smooth muscle cells, fibroblasts, or
perivascular adipocytes. Other homologues have not been found or are expressed at very low levels; their roles
have not been established. Nox1/Nox2 promote the development of endothelial dysfunction, hypertension, and
inflammation. Nox4 may have a role in protecting the vasculature during stress; however, when its activity is
increased, it may be detrimental. Calcium-dependent Nox5 has been implicated in oxidative damage in human
atherosclerosis. Critical Issues: NADPH oxidase-derived ROS play a role in vascular pathology as well as in the
maintenance of normal physiological vascular function. We also discuss recently elucidated mechanisms such as
the role of NADPH oxidases in vascular protection, vascular inflammation, pulmonary hypertension, tumor
angiogenesis, and central nervous system regulation of vascular function and hypertension. Future Directions:
Understanding the role of individual oxidases and interactions between homologues in vascular disease is
critical for efficient pharmacological regulation of vascular NADPH oxidases in both the laboratory and clinical
practice. Antioxid. Redox Signal. 20, 2794–2814.
Introduction
Reactive oxygen species (ROS) play an important role inthe development of cardiovascular disease, including
hypertension, atherosclerosis, diabetes, cardiac hypertrophy,
and heart failure. Vascular ROS production is essential in all
of these conditions as well as in the maintenance of normal
vascular homeostasis (76, 164). In the vasculature, several
differentially localized and expressed enzyme systems con-
tribute to ROS formation. These include the nicotinamide
adenine dinucleotide phosphate (NADPH) oxidases, endo-
thelial nitric oxide (NO) synthases, enzymes of the respiratory
chain, cytochrome P450 monoxygenases, and xanthine oxi-
dase. While all of these systems are important in various
disease states, NADPH oxidases seem to play the central role
in orchestrating the activation and dysfunction of other en-
zymes. Initial generation of ROS by NADPH oxidases triggers
the release of ROS from other sources (109). NADPH oxidase
homologues are differentially expressed in the vascular wall,
including endothelial cells, smooth muscle cells (SMCs), fi-
broblasts, and infiltrating immune cells (110). The expression
profile of NADPH oxidases varies not only between different
disease states, but also at various stages of the disease such as
atherosclerosis. In general, it is accepted that under physio-
logic conditions, vascular NADPH oxidases have a relatively
low level of constitutive activity. However, enzyme activity
can be increased both acutely and chronically in response to
stimuli such as cytokines (38), growth factors (23), hyperlip-
idemia, and high glucose (94), which disrupts vascular ho-
meostasis and results in pathology.
While the role of vascular NADPH oxidases has been
well described in pathology, their physiological functions
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remain less clear. We have recently gained substantial in-
sight into the contribution of individual NADPH oxidase
homologues in the maintenance of normal vascular func-
tion. In particular, the role of Nox4 in the regulation of
endothelial function was clearly defined (166). This review
focuses on the role of vascular NADPH oxidases in physi-
ological and pathological processes in the vasculature, with
particular emphasis on recently elucidated mechanisms
such as the role of NADPH oxidases in vascular protection,
vascular inflammation, pulmonary hypertension, and tu-
mor angiogenesis. Finally, we briefly discuss the possibil-
ities of pharmacological regulation of vascular NADPH
oxidases and inhibitors being developed, in both the labo-
ratory and clinical wards.
Localization, Structure, and Basic Functions
of Major Nox Isoforms in Vasculature
Vascular Nox isoforms have six transmembrane domains,
including alpha helices with cytosolic N- and C-termini,
which participate in electron transfer, leading to the reduction
of molecular oxygen to superoxide anion. Electron flow and
thus ROS production is tightly controlled by the interactions
of Nox subunits with other proteins, subunit phosphoryla-
tion, or elevation of intracellular calcium (15). There are seven
isoforms of NADPH oxidases expressed in mammals: Nox1,
Nox2, Nox3, Nox4, Nox5, Duox1, and Duox2. Four (Nox1,
Nox2, Nox4, and Nox5) are most commonly expressed in
vascular cells, while other homologues have not been found
or are expressed at very low levels; thus, their role has not
been established so far.
Nox2
Initially termed gp91phox, it has been cloned and identified
as a phagocytic respiratory burst oxidase, critical for the initial
nonspecific host defense. In addition to phagocytes, it is the
most widely expressed vascular NADPH oxidase isoform. It
is expressed in vascular smooth muscle cells (VSMCs), ad-
ventitial fibroblasts, endothelial cells, and perivascular adi-
pocytes (92, 149, 188). This NADPH oxidase homologue has
been characterized in detail and consists of the following
subunits: gp91phox (glycoprotein-91 kDa phagocytic-
oxidase, newly termed Nox2), p22phox, p47phox, p67phox,
p40phox, and the GTPase Rac1. The gp91phox and p22phox
subunits are membrane bound and together form cytochrome
b558, located in cytoplasmic vesicles and the plasma mem-
brane (20). The structure of this oxidase in vascular cells is
similar to that found in phagocytes, although it may have
additional or different regulatory subunits in selected condi-
tions. In particular, Nox organizer protein 1 (NoxO1) and Nox
activator protein 1 (NoxA1), initially discovered as Nox1
regulators (in place of p47phox and p67phox, respectively),
may also have modest activating properties toward Nox2
(100). In endothelial cells, Nox2-derived ROS are important
for p38 MAP-kinase-mediated proliferation and vascular en-
dothelial growth factor (VEGF)-induced migration (187).
Nox2 that is expressed in endothelial cells is involved in the
regulation of numerous functions of the endothelial cell. For
example, Nox2 activation affects NO bioavailability, and
modulates expression of adhesion molecules during inflam-
mation and angiogenesis. These will be further discussed
next.
Nox1
Nox1 (Mox1, NOH1) has been identified as the first ho-
mologue of Nox2 (7). It shares a 60% amino-acid sequence
identity with Nox2. Similar to its phagocytic homolog, Nox1
contains six transmembrane domains and conserved motifs
corresponding to binding sites of heme, flavin, and NADPH.
Nox1 is expressed in endothelial, smooth muscle, and ad-
ventitial cells of the vasculature. Most of the studies using
recombinant Nox1 protein show localization in cell mem-
branes, particularly in the plasma membrane (85). Using im-
munofluorescence microscopy, endogenous Nox1 protein
displayed surface distribution along the cellular margins
where it co-localized with caveolin-1 (33, 87). Other studies
showed endogenous or overexpressed Nox1 protein localized
to the nucleus, cytosol (28), endoplasmic reticulum (ER) (2),
and mitochondria (40). Nox1 activity requires p22phox,
NoxO1 (or possibly p47phox in some cases), and NoxA1, and
the small GTPase Rac. Nox1-dependent ROS generation
has been shown to play a pivotal role in cell signaling, cell
growth, angiogenesis, and cell motility (6). Interestingly, ROS-
generated via Nox1 have been reported to contribute to a
growing number of diseases involving vasculature, including
atherosclerosis, hypertension, neurological disorders, in-
flammation, and cancer (35, 142), which will be further dis-
cussed next. However, while highly expressed in animal
models of vascular disease, Nox1 appears to be only ex-
pressed at low levels in human peripheral or coronary vessels
(79, 80).
Nox4
This Nox isoform is a 67 kDa protein sharing a 39% amino-
acid sequence identity with Nox2. It was initially detected in
the kidney; therefore, it was termed Renox or kidney oxidase
(KOX) (62). However, it was soon identified in vascular walls,
particularly VSMCs, fibroblasts (15), and endothelial cells (64,
65). Studies of human coronary arteries have shown Nox4 to
be expressed predominantly in the media (170). It has been
suggested to be involved in stress signal transduction in the
kidney (67) and SMCs (151). Nox4 mediates transforming
growth factor b (TGF-b)-induced differentiation (173), insulin
signaling (130), oxygen sensing (115), cardiac differentiation
(116), and transcriptional regulation (107). Nox4 is predomi-
nantly localized at the ER (142, 151) and in the nucleus (40,
166). In addition, co-localization of Nox4 with the cytoskele-
ton and focal adhesions has been demonstrated (36, 87, 128).
Enzymatic activity of Nox4 mainly depends on the expression
level of Nox4 and p22phox and likely does not need any
further activation (131). Currently, it is unclear which type of
ROS is predominantly generated by Nox4. Unlike Nox1 or
Nox2 that primarily produce O2
- c, Nox4 has been shown to
produce hydrogen peroxide (H2O2) (43, 85). Production of
H2O2, rather than O2
- c, by Nox4 is possible due to a highly
conserved histidine residue in the E-loop of Nox4 that pro-
motes rapid dismutation of O2
- c before it leaves the enzyme
(177). This aspect of Nox4 biology needs to be further clarified.
Physiological roles of Nox4 differ depending on cell type and
stimulus. Nox4 might have an antagonistic function to Nox1
and Nox2 (166). Nox4 is implicated in both pro- and anti-
apoptotic pathways. It is needed for 7-ketocholesterol- in-
duced apoptosis in SMCs (151), while silencing of the protein
induces apoptosis in pancreatic cancer cells (136). Nox4 is
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important for the differentiation of cardiac cells from mouse
embryonic stem cells (116) and myofibroblasts from cardiac
fibroblasts (37). Differentiated VSMC require Nox4 to main-
tain expression of differentiation markers, smooth muscle
major histocompatibility complex (MHC), alpha -actin, and
calponin (36). Recent studies raise important questions re-
garding the major physiologic and pathologic roles of Nox4.
While Nox4 contributes to oxidative stress, compelling evi-
dence from Nox4 - / - mice indicates that endogenous Nox4
protects the vasculature during ischemic or inflammatory
stress (166). Interestingly, we have recently found that Nox4
expression is decreased in human abdominal aortic aneurysm
(AAA) in spite of largely increased oxidative stress in the
walls of AAAs (74). Moreover, Nox4 immunoreactivity has
been demonstrated in the nucleus and nucleolus of VSMCs by
confocal microscopy (87). A recent study has identified a no-
vel nuclear-localized Nox4 splice variant with a size of
28-kDa, Nox4D, which lacks putative transmembrane do-
mains (3). The possible functional role of nuclear Nox4 has
been previously described (87). Interestingly, Nox4D over-
expression results in increased NADPH-dependent ROS
production and causes increased phosphorylation of extra-
cellular signal-regulated kinase1/2 and the nuclear tran-
scription factor Elk-1 (3). Thus, Nox4D may have important
pathophysiologic effects through the modulation of nuclear
signaling and DNA damage; however, its role in vascular
biology should be further elucidated.
Nox5
Nox5 is expressed in primates but does not naturally occur
in rodents. It has been found in leukocytes, in the testis
(during development), and in lymphatic tissue. Expression of
lesser extent has been reported in ovaries, pancreas, and
placenta (8, 32). Recent studies have also identified the pres-
ence of Nox5 in vasculature, namely in endothelial cells and
VSMCs, where it is localized in the ER and the plasma
membrane (16). Nox5 has been reported to produce both su-
peroxide and H2O2; Nox5 is activated by Ca
2 + and does not
appear to require other subunits, although it may associate
with p22phox. The basic transmembrane structure of Nox5 is
similar to that described for other Nox isoforms, but what
distinguishes Nox5 is a unique N-terminus which encodes
four calcium-binding EF hands (Fig. 1) (8). We have identified
a calcium-dependent Nox5 protein and mRNA in human
coronary vasculature, in both endothelium and vascular me-
dia, which was functionally linked to calcium-dependent
NADPH-oxidase activity (75).
Diverse Mechanisms of Activation and Regulation
of Vascular NADPH Oxidases
Despite similarities in core structures, vascular Nox ho-
mologues have different mechanisms of activation. Activation
as well as its consequences may be different in the endothe-
lium (Fig. 2) or VSMCs (Fig. 3) or other cells such as peri-
vascular adventitial fibroblasts or adipocytes Nox1 and 2
require association with cytosolic components (p47phox,
p67phox or NoxO1 and NoxA1), Nox4 is constitutively active,
and Nox5 is activated by an elevation in intracellular Ca2 + .
The activation mechanism of Nox2 is most clearly defined and
similar to that described in phagocytes. On activation,
p47phox is phosphorylated and translocates to the mem-
brane, through the formation of a complex with p67phox and
p40phox. Phosphorylation of p47phox induces a conforma-
tional change in a tandem SRC Homology 3 (SH3) domain
that enables binding to a proline-rich region in the cytosolic
C-terminus of the transmembrane subunit p22phox. In-
dependently, the GTP-binding protein Rac also moves to the
membrane and activation occurs (15). In contrast to Nox2, the
Nox4-based oxidase appears to be constitutively active and
does not require p47phox, p67phox, or Rac.
Sustained activation of vascular NADPH oxidases occurs
in response to numerous agonists. Vascular NADPH oxidases
are responsive to several growth (platelet-derived growth
factor [PDGF], epidermal growth factor [EGF], and TGF-b),
FIG. 1. Nox5 expression
and function in human ath-
erosclerosis. Based on Guzik
et al. (75).
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cytokines (e.g., tumor necrosis factor, interleukin-1 [IL-1], and
platelet aggregation factor), mechanical forces (cyclic stretch,
laminar, and oscillatory shear stress), metabolic factors (hy-
perglycemia, hyperinsulinemia, free fatty acids, and ad-
vanced glycation end products), and G protein–coupled
receptor agonists (serotonin, thrombin, bradykinin, en-
dothelin, and angiotensin II [Ang II]) (71, 152, 154). In addi-
tion, c-Src, p21Ras, protein kinase C (PKC), phospholipase D,
and phospholipase A2 (PLA2) have been demonstrated to play
key roles in signaling involved in vascular NADPH oxidase
activation (1, 12, 39).
Ang II is one of the key agonists stimulating Nox1 and
Nox2 oxidase subunit expression as well as oxidase activation
in vascular cells and neutrophils (148, 156, 187). However, its
effects on Nox4 and Nox5 are much less pronounced and
perhaps indirect, which will be further discussed next (37, 111,
139). Ang II-induced production of ROS by VSMCs is initially
PKC-dependent (early phase), whereas the prolonged phase
( > 30 min) is dependent on Rac, Src, and phosphatidylinositol
3-kinase (167). Ang II increases mRNA levels not only of Nox
proteins but also of p22phox and p67phox (55, 148). Ang II-
dependent or H2O2-induced activation of Nox4 in mesangial
cells or cardiac fibroblasts has been reported to be dependent
on PLA2 and release of arachidonic acid (37, 86).
Cytokines have also been shown to regulate vascular
NADPH oxidases, which links inflammation with oxidative
stress. In particular, tumor necrosis factor-a (TNF-a) stimu-
lates NADPH oxidase Nox1, Nox2, and Nox4 expression and
activation in a variety of vascular cells (4, 11, 138). Other
stimuli that induce vascular NADPH oxidases include ER
stress (151), shear stress (91), or an elevation of intracellular
Ca2 + , which could act as an upstream signal to activate Nox
during cellular stress. The Nox5 isoform contains multiple EF-
hand Ca2 + -binding domains in the N-terminal region, al-
lowing its activation through calcium sensing (8). Calcium
binding induces a conformational change in the N terminus
of Nox5, resulting in the exposure of a hydrophobic motif,
which leads to a direct interaction between the regulatory N-
terminus and the catalytic C-terminus. This intra-molecular
interaction is likely to be responsible for Ca2 + -induced Nox5
activation (9), as it enables electron flow to the heme moieties
and, consequently, drives superoxide production.
Redox regulation of vascular NADPH oxidase activation
provides both negative feedback and feed-forward regulation
mechanisms. For example, Rac1 protein turnover is strongly
dependent on the redox status of the cell, creating a negative
feedback mechanism (106). At the same time, a feed-forward
mechanism exists (118), by which exogenous exposure of
SMC or fibroblasts to H2O2-activated NADPH oxidase stim-
ulates them to produce endogenous O2
- c, thereby amplifying
the vascular injury process. The self-limiting mechanism
could predominate during physiologic conditions, and be
involved in maintaining low output of the nonphagocyte
NADPH oxidase, whereas the feed-forward mechanism
may have a role in NADPH oxidase-dependent oxidative
stress in a variety of diseases, including atherosclerosis and
inflammation.
NADPH Oxidases in Vascular Pathobiology
The complexity of vascular NADPH oxidase systems
makes it difficult to unequivocally define the role of individ-
ual Nox oxidases in vascular physiology and pathology.
Several genetically modified mouse strains with either re-
moved or overexpressed Nox proteins have been used to in-
vestigate the roles of NADPH oxidases in the vasculature
(Table 1). Such studies have clearly linked Nox1, Nox2, and
Nox4 to the pathogenesis of vascular diseases, while other
FIG. 2. Selected interactions be-
tween NADPH oxidases in the
endothelium. While certain func-
tions were demonstrated for selected
homologues, high redundancy of
functions is expected. To see this il-
lustration in color, the reader is re-
ferred to the web version of this
article at www.liebertpub.com/ars
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Nox isoforms showed little to no vascular expression or in-
volvement. Obviously, this approach is not optimal for
studies involving Nox5, which would require a more complex
humanized model approach. Numerous studies in animal
models and in humans have also characterized the role of Nox
proteins in the most common vascular disease states such as
atherosclerosis, hypertension, and diabetes, which will be
discussed next.
Atherosclerosis
A number of studies have investigated the role of indi-
vidual NADPH oxidases in atherosclerosis in animal models.
Nox2 levels were increased in the aortas of apolipoprotein E
(ApoE) - / - atherosclerotic mice, while Nox4 levels were not
significantly different between ApoE - / - and wild type (97).
However, studies using deletion of the Nox2 gene in ApoE - / -
mice have not been fully consistent. Nox2/ApoE double
knockout mice, which had been fed a high fat diet, were found
to have no obvious protection against atherosclerosis when
examining aortic sinus sections, in spite of decreased vascular
superoxide formation (102). Similar surprising results were
reported in global p47phox knockout mice crossed with
ApoE - / - mice (90). Endothelial-targeted Nox2 over-
expression in ApoE - / - mice was sufficient to increase vas-
cular superoxide production, endothelial cell activation, and
subsequently increased macrophage recruitment. This initial
increase in macrophage recruitment did not alter the pro-
gression of atherosclerosis (50). In contrast to these studies,
Barry-Lane et al. found that total aortic lesion area (from
arch to bifurcation) was reduced in p47phox knockout mice
crossed with ApoE - / - mice, suggesting that Nox1 and/or
Nox2 may be involved in atherogenesis (10). Such dis-
crepancies in the findings regarding the vascular conse-
quences of p47phox - / - could be due to several reasons. An
example is the inclusion of assessments of different areas from
aortic lesions (sinus vs. whole aorta). Another reason for the
differences may also be related to the removal of p47phox,
which causes immunodeficiency. These mice are prone to sub-
clinical infections that are characterized by splenomegaly and
inflammation which could counteract the anti-atherosclerotic
effect of the loss of NADPH oxidase. While studies in animal
models are conflicting, a genetic hereditary deficiency of
NADPH oxidases, particularly Nox2 (gp91phox), occurs in
humans with chronic granulomatous disease (CGD). In hu-
mans, the genetic deficiency of Nox2 is associated with
FIG. 3. Diversity of functional consequences of the activation of NADPH oxidases in vascular smooth muscle cells and
perivascular tissues. To see this illustration in color, the reader is referred to the web version of this article at www
.liebertpub.com/ars
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enhanced endothelium-dependent flow-mediated vaso-
relaxation, and decreased markers of vascular aging and oxi-
dative stress (192). Importantly, diminished atherosclerosis
burden has been described in these patients, which empha-
sizes the possible role of Nox2 oxidase in atherosclerosis (191).
Although promising, these observations should be inter-
preted carefully, as CGD is a serious disease leading to im-
portant changes in the immune system, which could affect
vasculature in a number of additional ways.
Nox4 may also participate in atherogenesis, although much
less is known in this regard. It has been shown, however, that
Nox4 regulates VSMC migration and differentiation, which is
critical for neo-intima formation (128). In human atheroscle-
rosis, Nox4 expression is increased in intimal lesions of cor-
onary arteries (170). Similarly, Nox1 overexpression in the
media results in increased neo-intima formation on vascular
injury (114).
Numerous studies have looked at vascular NADPH oxi-
dases in human atherosclerosis. Our group as well as others
have characterized NADPH oxidases in human coronary ar-
teries with evident atherosclerotic plaques (75, 79, 170), as
well as in peripheral arteries and veins without plaques but
characterized by systemic endothelial dysfunction (73, 74, 80–
82). The NADPH oxidase is predominantly Nox2-based in
veins, whereas an Nox4-based oxidase appears proportio-
nately more important in human mammary or radial arteries
(80). In veins, the predominance of Nox2 expression may also
suggest the major contribution of endothelium and adventitia
to total vascular ROS production, as these contain Nox2-
based oxidases (14), potentially contributing to endothelial
dysfunction (160, 170, 175). However, the cellular expression
of individual oxidases has not been clearly established. While
initial studies in human vessels suggest that Nox2 is not
usually present in medial VSMCs, it has been demonstrated
that human microvascular SMCs can express Nox2 in re-
sponse to Ang II (182). Meanwhile, Nox4 expression is in-
creased by oscillatory versus pulsatile flow, which could be
particularly relevant to the development of atherosclerotic
plaques in the regions of turbulent flow (91). This clearly il-
lustrates that Nox isoform expression in human vascular cells
is regulated in a complex manner that depends on the cell type
predominating in different vessels and on the nature of
pathophysiologic stimuli.
Still, it is vital to emphasize that overall, enzymatic sources
of O2
- c in coronary arteries are similar to those of peripheral
arteries (18, 78). In summary, Nox2, Nox4, Nox5, p22phox,
and, to a lesser extent, Nox1 are expressed in human pe-
ripheral and coronary vessels, which may contribute to ath-
erosclerosis (80, 170). Nox1 expression directly alters cell
proliferation (174), and treatment of VSMC with Ang II or
PDGF up-regulates Nox1, while down-regulating Nox4 (111).
Vascular injury increases expression of Nox1, Nox2, and
p22phox, while Nox4 increases later (175), coinciding with a
reduction in the rate of VSMC proliferation. Taken together,
these findings suggest that while Nox1 and Nox2 are involved
in acute response to injury or to Ang II stimulation, Nox4 is
involved in maintaining the quiescent VSMC phenotype
(175). Thus, a high Nox2/Nox4 ratio in veins could partially
account for the susceptibility to intimal hyperplasia, re-
modeling, and accelerated atherosclerosis in vein grafts (197);
whereas a lower Nox2/Nox4 ratio in mammary artery grafts
could convey less susceptibility to atherosclerosis. Functional
consequences of increased NADPH oxidase activity also in-
clude the effects on lipid oxidation, which is a critical step in
Table 1. Selected Mouse Models Used to Study the Importance of Vascular
NADPH Oxidases and Their Functional Effects
Disease Mouse model Effect on disease References
Atherosclerosis Double knockout
Nox2 - / - /ApoE - / -
No change in lesion area in the aortic sinus Kirk et al. (102)
Double knockout
p47 - / - /ApoE - / -
No change in lesion area in the aortic sinus; Hsich et al. (90)
Decreased total aortic lesion area Barry-Lane et al. (10)
Nox2 endothelium-specific
overexpression in ApoE - / -
Increased, vascular inflammation, and
oxidation but not atherosclerosis.
Douglas et al. (50)
Nox1 VSMC overexpression Increased neointima on wire injury Lee et al. (114)
Hypertension Nox1 - / - Decreased BP and O2
- levels Matsuno et al. (132),
Gavazzi et al. (60)
Nox1 VSMC overexpression Increased BP Dikalova et al. (44)
Nox2 - / - No change in BP Touyz et al. (182)
Decreased BP Jung et al. (98),
Wang et al. (193)
Nox4 - / - No change in BP Kleinschnitz et al. (103)
p47 - / - Decreased BP and O2
- c levels Landmesser et al. (108),
Lavigne et al. (113)
Pulmonary
hypertension
Nox4 - / - No change in pulmonary blood pressure
but prevention of poststroke
neurodegeneration
Kleinschnitz et al. (103)
Cardiac failure Nox1 - / - ; Nox2 - / - Effect on infarct size in myocardial
ischemia/reperfusion; Decreased
hypertrophy; Increased cardiac hypertrophy
Braunersrenther V et al.
(23a)
Bendall et al. (17)
Byrne et al. (25)
Nox4 - / - Decreased cardiac hypertrophy and failure Kuroda et al. (107)
ApoE, apolipoprotein E; NADPH, nicotinamide adenine dinucleotide phosphate; VSMC, vascular smooth muscle cell.
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the initiation of atherosclerotic plaque development. For in-
stance, Nox4 expression elevates in relation to oscillatory flow
and coincides with increased oxidative stress and low-density
lipoprotein (LDL) oxidation (91), while NADPH oxidase
activity is correlated with oxidized-LDL in carotid plaques.
Despite the differences in the expression levels between
individual Nox homologues, the expression of both p22phox
and Nox4 mRNA is strikingly correlated in human arteries
and veins (80). This indicates that risk factors for athero-
sclerosis may be critical for the systemic regulation of
NADPH oxidase expression (80). Indeed, activity and ex-
pression of major NADPH oxidase components is correlated
to the number of major risk factors for atherosclerosis in
humans (82).
Finally, Nox5 is an important source of ROS in athero-
sclerosis (75). Nox5 mRNA and Nox5 protein are dramatically
increased in human coronary arteries obtained from pa-
tients with coronary artery disease. These correlate with the
Ca2 + -dependent NADPH oxidase activity in arteries. Nox5
was expressed in the endothelium of early-stage lesions
and in VSMCs in the intima of advanced coronary lesions
(Fig. 1) (75).
In summary, differential generation of ROS by functionally
distinct NADPH oxidase isoforms expressed in different
vascular cell types in atherosclerosis may be used as a thera-
peutic advantage. For example, Nox2-based production of
ROS predominates in the endothelium and adventitia,
whereas Nox1 and/or Nox4 could be much more important
in VSMC (158), as their expression and activity differs de-
pending on the stage of the disease. Thus, one could postulate,
that if we were able to specifically inhibit these individual
oxidases, we would be able to affect distinct stages in vascular
disease processes.
Hypertension
Vascular NADPH oxidases are probably characterized in
most detail in relation to hypertension. This was one of the
first pathologies in which NADPH oxidases were clearly im-
plicated (156). Ang II plays an important role in the devel-
opment of hypertension and is one of the most important
inducers of increased NADPH oxidase-dependent superoxide
production in VSMCs (48) and throughout the vascular wall
(141). The effects of Ang II on NADPH oxidases are mediated
primarily via the angiotensin receptor type 1 (AT1) receptor
(79). NADPH oxidases also participate in Ang II-stimulated
intracellular H2O2 production, which mediates vascular hy-
pertrophy (205). Ang II increases the expression of several
NADPH oxidase homologues (Nox1, Nox2, Nox4, and
p22phox) (156), all of which may to some extent participate in
the pathogenesis of hypertension and associated vascular
dysfunction. Nox1 is increased in the aortas of aged sponta-
neously hypertensive rats (SHRs) in parallel with increased
NADPH oxidase activity. While Nox2 was also up-regulated,
Nox4 protein levels were unchanged or even decreased in the
aortas of SHRs (198). Overexpression of Nox1 in mouse
VSMCs caused a marked increase in systolic blood pressure
and hypertrophy in response to Ang II (44). In contrast,
deletion of Nox1 in mice results in a blunted hypertensive
response to Ang II and protects from development of endo-
thelial dysfunction, oxidative stress, vascular hypertrophy,
and aortic dissection (60, 61, 132). Overexpression of p22phox
in VSMCs leads not only to up-regulation of Nox1-based
oxidase in the vessel wall, but also to increased hypertensive
responses to Ang II (112, 195). At the same time, silencing of
p22phox in rats prevents a slow pressor response to Ang II
(137). Similarly, p47phox knockout mice, which have deficient
Nox1 (and Nox2) activation, exhibit reduced hypertension
and preserved endothelial function after chronic Ang II
treatment (108, 109). VSMCs from p47phox-deficient mice do
not produce superoxide (113). Moreover, local overexpression
of Nox1 in VSMCs has profound effects on other cell types
in the vessel wall. For example, this can lead to the oxidation
of tetrahydrobiopterin (BH4) in endothelial cells and endo-
thelial nitric oxide synthase (eNOS) uncoupling, resulting in a
decrease of NO bioavailability and causing endothelial dys-
function (45). In contrast, Nox2 - / - mice were reported to
have only modestly altered (193) or even unaltered (183)
blood pressure responses to Ang II, suggesting that this iso-
form may be less important in blood pressure regulation, but
still showing effects on vascular hypertrophy (193) and en-
dothelial dysfunction during experimental hypertension
(98). In addition, Nox2 was critical for cardiac hypertrophy in
Ang II-dependent hypertension (17), but not in a pressure-
overload-dependent model, where hypertrophy might be
related to other homologues such as Nox4 (25). While gene-
specific deletion or overexpression approaches have proved
useful in defining the role of Nox1and Nox2 in the vascular
system, the functional importance of Nox4, while undeniable,
has been raising the most controversy and discussion.
Endothelium-targeted Nox4 overexpression causes enhanced
vasodilation and reduced basal blood pressure, suggesting a
protective role for Nox4 that has been linked to increased
H2O2 production by Nox4 (157). In the absence of pathogenic
stimuli, Nox4 knockout mice do not have an obvious phe-
notype and are normotensive (176). However, more recent
data have convincingly shown that in vascular pathologies,
Nox4 may serve as a protective oxidase (22, 166). In the con-
ditions associated with stress induced by ischemia or by Ang
II, loss of Nox4 resulted in reduction of eNOS expression, NO
production, and heme oxygenase-1 (HO-1) expression. These
changes were associated with apoptosis and inflammatory
activation in Nox4 - / - mice (166). These effects were partially
related to Nrf-2 induction. Consequently, there is now clear
evidence that endogenous Nox4, in contrast to Nox1 and
Nox2, may protect the vasculature during ischemic or hy-
pertensive stress (166). However, this may not be the case in
the brain, where Nox4 has been shown to contribute to oxi-
dative stress related to stroke and other pathologic conditions
(103). Hence, further studies are needed to determine whether
Nox4 is always protective or whether it can become dys-
functional.
Moreover, while the role of Nox1 in the pathogenesis of
hypertension appears to be relatively well documented,
chronic models of high renin transgenic overexpression do
not show significant effects of Nox1 on blood pressure in this
model of hypertension (204).
Diabetes
Diabetes is associated with a variety of metabolic abnor-
malities, such as insulin resistance and hyperglycemia.
However, cardiovascular complications are the major cause
of mortality in diabetic patients. ROS generated during
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hyperglycemia are implicated in the development of endo-
thelial dysfunction and progression of diabetic vascular
complications. Endothelial dysfunction characterized by in-
creased NADPH oxidase-dependent ROS generation has been
demonstrated in animal models of diabetes (88), and in pa-
tients with diabetes (82). In aortas from the streptozotocin
(STZ)-induced diabetic ApoE - / - mice, levels of Nox2 and
Nox4 are increased (47). Similarly, in db/db mice, Nox1 or
Nox4 are up-regulated, which is associated with increased
ROS production and inflammation, indicating a potential role
of Nox1 and Nox4 in diabetic macrovascular disease (119).
Another recent study has elegantly addressed the role of Nox1
in diabetic vasculopathy using the specific Nox inhibitor
GKT137831, as well as Nox1 - / - mice on an ApoE - / - back-
ground in which diabetes has been induced (69). Deletion of
Nox1, but not Nox4, had a profound anti-atherosclerotic effect
correlating with reduced ROS formation, diminished che-
mokine expression, reduced vascular adhesion of leukocytes,
reduced macrophage infiltration, and reduced expression of
proinflammatory and profibrotic markers (69). Similarly,
treatment of diabetic ApoE-deficient mice with GKT137831
attenuated atherosclerosis development (69).
Hyperglycemia itself can induce vascular NADPH oxi-
dases. Incubation of human endothelial cells with red blood
cells isolated from patients with type 1 diabetes, but not from
normal volunteers, activated endothelial NADPH oxidase
and increased endothelial ROS generation, which was medi-
ated by advanced glycation end products on the surface of
red blood cells from diabetic patients (194). Hyperglycemia
increases NADPH oxidase expression, levels of oxidative
stress markers, and apoptosis (155) of human endothelial cells
in relation to increased NADPH oxidase subunit expression
(for example, p22phox and p47phox) (46). Similarly, in ar-
teries and veins, superoxide anion production is strongly in-
creased in diabetic patients, most prominently in the
endothelium (78). Superoxide anion produced in large
quantities by NADPH oxidases reduce NO bioactivity by
direct scavenging.
While NADPH oxidases play a key role, uncoupled eNOS
has also been shown to be a particularly important source of
ROS in diabetic blood vessels (88). Importantly, superoxide
derived from vascular NADPH oxidases leads to eNOS un-
coupling through oxidation of BH4 (88). Ang II is also in-
volved in the activation of vascular NADPH oxidases in
diabetes. AT1 receptor-mediated NADPH oxidase activation
appears to contribute to vascular insulin resistance, endo-
thelial dysfunction, apoptosis, and inflammation (196). While
vascular Nox4 does not appear to have a direct role in diabetic
vasculopathy (69), it may have indirect effects through the
regulation of adipogenesis (preadipocyte differentiation in
response to insulin) in metabolic syndrome (165).
Consequently, vascular NADPH oxidases have emerged as
potentially important targets contributing to the pathogenesis
of long-term cardiovascular complications of diabetes. Of the
numerous pathologies and vascular disease states, diabetic
vasculopathy may prove be the most interesting area for the
future application of NADPH oxidase inhibitors.
In summary, genetically manipulated mouse models as
well as studies in human vasculature have been very useful in
defining the functional importance of individual NADPH
oxidases. Further studies characterizing individual knockout
and overexpression of Nox isoforms, specifically in endothe-
lial cells, VSMCs, and fibroblasts will undoubtedly provide a
better understanding of the complex mechanisms involved in
NADPH oxidase activation and regulation. Studies of Nox5
expression in various models are now warranted to further
understand its role in the vasculature using these valuable
molecular tools.
Vascular NADPH Oxidases in Pulmonary Hypertension
Recently, significant progress has been made in our un-
derstanding of the role of vascular NADPH oxidases in pul-
monary hypertension. This is crucial, considering the clinical
consequences of pulmonary hypertension and a lack of suc-
cessful therapies. The major pathologic process in pulmonary
hypertension is chronic hypoxia-induced vascular remodel-
ing. It is characterized by malignant SMC hypertrophy and
proliferation within the pulmonary vessel media (123). This
leads to a decrease in vascular luminal area, increased vas-
cular resistance, and thus development of pulmonary hy-
pertension and increased right ventricular pressure. A role for
Nox2-based NADPH oxidase in this process has been sug-
gested, as all of these phenotypes are attenuated in Nox2 - / -
mice (123). This is consistent with the role of this oxidase in
VSMC hypertrophy, particularly pulmonary artery smooth
muscle cells (PASMCs) (93, 173).
However, the role of NADPH oxidases in pulmonary hy-
pertension appears to be more complex than simply stimu-
lating VSMC hypertrophy and proliferation. They may be
involved at very early stages of disease pathogenesis. ROS
derived from vascular Nox isoforms, in particular Nox2 and
Nox4, are involved in long-term responses of pulmonary
vasculature to hypoxia (52, 135). Thus, NADPH oxidases have
been suggested to serve as oxygen sensors in the lung. Inter-
estingly, Nox4 has been reported to be the predominant ho-
molog in human airways and in PASMCs (49). PASMCs are
particularly sensitive to oxygen availability and are respon-
sible for acute hypoxic vasoconstriction and the development
of pulmonary hypertension in response to chronic hypoxia
(72). Nox4 expression level has been increased in mice ex-
posed to chronic hypoxia and in isolated PASMCs exposed to
hypoxia. Diebold et al. have described a putative hypoxia
responsive element in the human Nox4 promoter and dem-
onstrated that this sequence is indispensable for the binding of
hypoxia-inducible factor-1a (HIF-1a) (42). In fact, RNA inter-
ference against HIF-1a suppressed the hypoxia-induced ex-
pression of Nox4 (42). In patients with idiopathic pulmonary
arterial hypertension, the level of Nox4 expression has been
up-regulated in the lung. Treatment of PASMCs with an anti-
Nox4 siRNA significantly reduced their proliferation.
Interestingly, it appears that Nox2 and Nox4 play coordi-
nated roles in the development of hypoxia-induced pulmo-
nary hypertension. Theoretically, endothelial ROS generation
by Nox2 may stimulate Nox4 up-regulation in the vessel
media, which would be important for hypoxia-dependent
PASMC proliferation (135). Hypoxia also increases the level of
TGF-b (97), which has been shown to induce Nox4 expression.
Inflammatory processes can also contribute to the induction
of Nox4 in pulmonary hypertension. In particular, nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-jB)
is involved in the hypoxia-induced expression of Nox4 in
PASMC, in that hypoxia increases the binding of NF-jB p65 to
the putative NF-jB binding site adjacent to the putative
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hypoxia-responsive element. Furthermore, activation of the
nuclear hormone receptor peroxisome proliferator-activated
receptor gamma (PPARc) attenuated hypoxia-induced Nox4
expression, pulmonary hypertension, and pulmonary vascular
remodeling (143). Rosiglitazone, a synthetic agonist of PPARc,
attenuated hypoxia-induced pulmonary hypertension and
vascular remodeling in the mouse and reduced hypoxic Nox4
induction and ROS generation in the lung (127). Thus, while
both Nox2 and Nox4 seem to be involved in pulmonary hy-
pertension, it appears that Nox4 may be involved in responses
to hypoxia as well as inflammation, and may be an important
target for novel pulmonary hypertension therapies.
Vascular NADPH Oxidases in Tumor
and Ischemic Angiogenesis
Another field in which vascular NADPH oxidases (mostly
endothelial and endothelial progenitor cells) seem to be
gaining importance is angiogenesis. It encompasses a wide
range of conditions ranging from physiological situations
such as embryogenesis and wound repair, to pathological
conditions such as diabetes, arthritis, and cancer. In endo-
thelial cells within the tumor, ROS have a critical role in
neovascularization during tumor growth (140), while the
thiol-antioxidant, N-acetylcysteine (NAC), attenuates endo-
thelium cells invasion and angiogenesis in an in vivo tumor
model (26). Vascular NADPH oxidases respond to various
pro-angiogenic factors such as VEGF, making them prime
targets in anti-angiogenic therapies. For example, Nox2-
derived ROS are important in signaling for cytoskeletal or-
ganization in endothelial cell migration (186). Similarly, Nox1,
Nox4, and Nox5 expression is increased in melanoma cells,
and affects neovascularization and angiogenesis in the tumor
(68). While being targets for pro-angiogenic factors, vascular
NADPH oxidases are important modulators of the release
of various angiogenesis-related factors, which are redox
sensitive. These include VEGF-A, HIF-1a, p53, and matrix
metalloproteinases (MMPs). Nox1-induced H2O2 increases
VEGF and VEGF receptor expression, and MMP activity,
markers of the angiogenic switch, thereby promoting vascu-
larization and rapid expansion of the tumors (6). Increased
VEGF expression and enhanced angiogenesis in experimental
atheromas have been demonstrated in transgenic mice over-
expressing Nox1 and Nox2 (101). Implantation of tumorigenic
B16F0 melanoma cells subcutaneously in wild-type mice has
resulted in vascularized tumors after 10 days. In Nox1 - / -
mice, the tumors that have developed have been smaller and
less vascularized. This reduction in angiogenesis was associ-
ated with a reduction in the expression of several genes, in-
cluding VEGF, MMP-2, MMP-9, and a reduction in NF-kB
activity (58).
In a similar fashion, NADPH oxidases participate in is-
chemic revascularization. Nox2 knockout mice showed re-
duced VEGF-induced new vessel formation (186) and delayed
the blood flow recovery in ischemic hind limbs (181). It
is noteworthy that Nox2 deficiency-induced impairment
of ischemic angiogenesis was associated with reduced endo-
thelial progenitor mobilization from the bone marrow in
response to ischemic insults (185). Impaired blood flow re-
covery in Nox2 - / - mice has been rescued by transplantation
of wild-type bone marrow cells into Nox2-deficient animals.
This indicates the therapeutic potential of targeting Nox in
endothelial progenitors in the treatment of ischemic cardio-
vascular diseases. The role of Nox5 in angiogenesis has also
been recently described. In human aortic SMCs, silencing of
Nox5 abrogated PDGF-induced proliferation via a JAK/STAT
signaling pathway (96). Nox5 also mediates thrombin-
induced formation of capillary-like structures in endothelial
cells, suggesting an additional role in angiogenesis (16).
While mechanisms of angiogenesis are well defined in both
ischemia and cancer, the role of vascular NADPH oxidases is
becoming clearer. Use of novel Nox inhibitors may turn out to
be a valuable strategy in future anti-angiogenic therapies,
although possible adverse effects on ischemic angiogenesis
should also be taken into consideration.
Seasonal Variation of Vascular NADPH Oxidase Activity
A recent study has reported an interesting phenomenon
that could have important implications for studies of vascular
NADPH oxidases (105). Activity and expression of vascular
NADPH oxidases may vary seasonally in both rats and mice
(and possibly in humans). Seasonal variation in endothelial
dysfunction and oxidative stress has been noted in humans
and rats, suggesting it to be a common phenomenon of po-
tential clinical relevance (89). The mechanism is still not fully
understood and has been related to changes in physical ac-
tivity. Interestingly, Langendorff-perfused guinea-pig and rat
heart preparations generated close to 100% more O2
- c, while
human subjects excreted 65% more 8-isoprostane in the
summer versus other seasons (105). Inhibitors of NADPH
oxidase, xanthine oxidase, and NO synthase prevented seasonal
O2
- c overproduction (105). In the summer, NADPH oxidase
and xanthine oxidase activity, and protein expression were in-
creased. Meanwhile, endothelial NO synthase and superoxide
dismutases were down-regulated, which was accompanied
by adhesion molecule up-regulation and the endothelial gly-
cocalyx destruction associated with these changes (105).
Moreover, during the summer, STZ-induced diabetes was
associated with greater vascular disturbance, in spite of sim-
ilar hyperglycemia (105). These findings are intriguing, as
they may indicate rhythmic regulation of Nox expression and
activity, which should be further investigated and verified.
NADPH Oxidases in the Regulation
of Vascular Inflammation
During the past several years, it has become apparent that
inflammation and oxidation are two basic processes under-
lying the pathogenesis of most disease states in humans.
Furthermore, it is now evident that these two distinct mech-
anisms are in a constant interplay, with interactions particu-
larly evident in the vessel wall (121, 134, 176). Vascular
oxidative stress regulates the development of vascular and
renal inflammation that has been recently implicated in the
pathogenesis not only of atherosclerosis but also of hyper-
tension and hypercholesterolemia (84).
The role of vascular NADPH oxidases in the regulation of
vascular inflammation has been initially defined in the path-
ogenesis of atherosclerosis. The expression of endothelial
adhesion molecules such as vascular cell adhesion molecule 1
(VCAM-1), intercellular adhesion molecule 1 (ICAM-1), and
P- and E-selectins on large vessel arterial lumen endothelial
cells is redox sensitive and dependent on Nox1, Nox2, and
Nox5 NADPH oxidases. This is in part, because they contain
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an NFjB site within the promoter region that is known to be
regulated in a redox-sensitive fashion (169). It is the earliest
and most critical step in the inflammatory process, which
leads to transmigration of leukocytes into the subendothelial
space (120, 144). This occurs not only in large vessels during
atherosclerotic lesion formation, but also in the endothelium
of the vasa vasorum, leading to accumulation of leukocytes in
the adventitia and outer media. It appears that perivascular
inflammation characterized by macrophage, dendritic cell,
and T- and B-cell accumulation, in the form of tertiary lym-
phoid structures, is a key feature of early atherosclerosis
(56, 99, 104) or hypertensive vascular dysfunction (77, 190).
Although the precise mechanism underlying this early pro-
cess is not entirely clear, NADPH oxidase-derived ROS are
increasingly being recognized as important players (117, 150).
Studies of coronary arteries from diabetic pigs have shown
that diabetes-induced increases in NADPH oxidase activity
are accompanied by up-regulation of inflammatory cytokines
(IL-6 and TNF-a), chemokines (monocyte chemoattractant
protein-1 [MCP-1]), and vascular cell adhesive molecules
(VCAM-1), providing further support for the role of NADPH
oxidase in vascular inflammation (206). In addition, NADPH
oxidases, via overproduction of O2
- c, mediate expression
and release of chemokines such as regulated on activation,
normal T cell expressed and secreted (RANTES), or chemo-
kine (C-C motif) ligand 2 (CCL2) from endothelium or
VSMCs, essential for leukocyte recruitment to the vascular
wall (29). ROS derived from adventitial fibroblasts may also
serve as a direct chemotactic signal for leukocytes (122) and
increase another chemotactic molecule, MCP-1 (201).
Scavenging of ROS by SOD and catalase suppresses the in-
duction of MCP-1 mRNA by TNF-a (31). Ang II, endothelin 1
(ET-1), and inflammatory mediators can modulate basal
NADPH oxidase-induced O2
- c production by affecting both
activation of the enzyme and expression of NADPH oxidase
subunits (55). Liu et al. have shown that Ang II infusion for 1
week increased NADPH oxidase-derived ROS production in
rat aortas, and enhanced ICAM-1 expression and subsequent
adventitial macrophage infiltration (122). Similarly, Ang II
infusion in mice induced a convergence of macrophages as
well as T cells to the adventitia (24). Finally, recent mecha-
nistic studies have shown a particular importance of Nox5 in
the regulation of vascular inflammation, which has been
linked to Fraktalkine gene expression (161). These effects are
particularly important in the light of recent observations,
showing that inflammatory cell activation is critical for the
development of hypertension (190) and vascular dysfunction
(83). However, these are not limited to the vasculature, as
NADPH oxidases and ROS are essential in regulating in-
flammation in other organs such as the lungs (66).
While vascular NADPH oxidases are important in the
regulation of inflammatory responses, NADPH oxidases are
also expressed in immune cells. Ang II-induced hypertension
is associated with increased Nox2-mediated superoxide pro-
duction and Nox2 expression in T cells and monocytes in
peripheral blood. This has been linked to the activation of
these cells and may be important in the pathogenesis of Ang
II-mediated hypertension. Furthermore, Nox4 is critical in
monocyte priming for chemotaxis and recruitment to the
vessel wall (184).
Understanding the complex interactions between vascular
oxidative stress and vascular inflammation has become pos-
sible, thanks to the development of novel strategies for
quantitative assessment of vascular inflammation in relation
to Nox activity and expression. Nevertheless, a further un-
derstanding of pro- and anti-inflammatory roles for vascular
oxidases is now necessary (176).
NOX-Derived ROS and Central Regulation
of Blood Pressure
Blood pressure regulation is a complex process involving
renal, vascular, and central mechanisms. The brain is essential
for processing and integrating neurohumoral signals from the
periphery to maintain pressure and fluid homeostasis.
NADPH oxidases have been identified as major producers of
ROS in the brain and are expressed in numerous brain
structures (19). Increased ROS production is seen in several
regions of the brain in hypertension, including the cir-
cumventricular organs (CVOs) (210), hypothalamic centers,
and the brainstem (146). Nox2 as well as Nox4 are the pre-
dominant homologues expressed in the fore-, mid-, and
hindbrain of mice, while Nox1 is detectable at very low levels
(92). However, Ang II induces expression of individual
NADPH oxidase homologues, particularly Nox2 in the brain,
which may be related to increased sympathetic nervous
system activation (92). Taken together, it is possible that an
increase in NADPH oxidase-derived ROS in CVOs, hypo-
thalamic nuclei, and brainstem sites plays a central role in the
neurocardiovascular dysfunction observed in hypertension
(21). Vascular NADPH oxidases could also be important, as
Nox2 appears to be a prominent mediator of the harmful ef-
fects of Ang II in the cerebral circulation during hypertension
(34). In addition, knock down of Nox2 and Nox4 proteins in
the paraventricular nucleus attenuated the development of
Aldosterone/NaCl-induced hypertension (202). Silencing
Nox2 or Nox4 alone in the subfornical organ (SFO) signifi-
cantly attenuated the central Ang II-induced pressor re-
sponse, while silencing both Nox2 and Nox4 together
abolished this response. In contrast, silencing Nox2, but not
Nox4, significantly attenuated the central Ang II-induced
dipsogenic response, showing the different roles of Nox2 and
Nox4 in the regulation of hypertension and the dipsogenic
response (153). Nox2 and its cytosolic components (p40phox,
p47phox, and p67phox) are expressed in the rostral ventro-
lateral medulla (RVLM) of rabbits, and are increased by in-
tracerebroventricular Ang II administration (57). Similar
findings were described in rat RVLM (30), additionally
showing that Ang II increased the serine phosphorylation of
p47phox, suggesting NADPH oxidase assembly and activa-
tion. Lob et al. showed, in turn, that deletion of p22phox from
the SFO brain region diminished the hypertensive response
and eliminated peripheral vascular inflammation caused
by Ang II (126). Inhibition of NADPH oxidase in the SFO
repressed the cardiovascular and dipsogenic effects to in-
tracerebroventricular administration of Ang II (208). In ad-
dition, there is compelling evidence that superoxide anion is
necessary to elicit the vasopressor, bradycardic, and dipso-
genic responses produced by the intracerebroventricular ad-
ministration of Ang II (209). Selective deletion of superoxide
dismutase 3 (SOD3) in the SFO specifically increases Ang II-
induced vascular T-cell and leukocyte infiltration in addition
to increasing sympathetic modulation of heart rate, blood
pressure, and vascular O2
- (125). These studies provide
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compelling evidence for the role of ROS in the central regu-
lation, not only of hypertension but also of vascular inflam-
mation. However, we now need to clearly identify whether
oxidative stress leads to increased sympathetic nervous sys-
tem activation or whether it is the latter that controls induc-
tion of oxidative stress in hypertension, atherosclerosis, or
other cardiovascular disorders.
NADPH Oxidase Inhibitors—Vascular Effects
Several classes of drugs currently used in clinical prac-
tice, such as medications affecting the renin-angiotensin-
aldosterone system (133), statins (5, 162), and calcium channel
blockers (203), have been shown to decrease NADPH oxidase
activity and/or expression (76, 164). Moreover, some natu-
rally occurring polyphenols may effectively inhibit NADPH
oxidases in the vasculature or platelets, apart from simple
scavenging of ROS (163). Understanding the importance of
vascular NADPH oxidases and their potential value as ther-
apeutic targets has sparked a search for specific and efficient
Nox enzyme inhibitors. This is reviewed in depth elsewhere
in this Forum. We have summarized selected vascular effects
of NADPH oxidase inhibitors in Table 2. However, it should
be noted that the specificity and selectivity of many of these
compounds is under constant revision, and this aspect should
be very carefully considered when designing new studies and
trials.
Conclusion
NADPH oxidase-derived ROS can act as vital signaling
molecules or can cause toxicity depending on the time and
cellular localization of Nox enzyme expression. This is par-
ticularly evident in the cardiovascular system. Therefore, a
systematic and detailed characterization of NADPH oxidases
in relation to the complex setting of cardiovascular diseases is
warranted. Within recent years, we have further understood
the complexity of this problem. For example, it is very difficult
to draw a clear line between the protective and damaging
effects of Nox4-derived ROS. In addition, discrepancies be-
tween studies looking at the consequences of Nox4 inhibition
or Nox4 knockout should be further explained. We have also
understood that expression and activity of NADPH oxidases
should be very closely regulated, as either too much or too
little of NADPH oxidase-derived ROS is detrimental. Thus,
we need to learn how to tightly control/carefully affect their
activity. Particularly, we need development of Nox oxidase-
specific inhibitors, which would enable us to differentiate
between various Nox homologues. Fortunately, much prog-
ress has been made in this field, and we are getting closer to
this important goal.
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Abbreviations Used
17DMAG¼ 17-dimethylaminoethylamino-17-
demethoxygeldanamycin
AAA¼ abdominal aortic aneurysm
AEBSF¼ 4-(2-aminoethyl)-benzenesulfonylfluoride
Ang II¼ angiotensin II
ApoE¼ apolipoprotein E
AT1¼ angiotensin receptor type 1
BH4¼ tetrahydrobiopterin
Ca2+¼ calcium
CCL2¼ chemokine (C-C motif) ligand 2
CGD¼ chronic granulomatous disease
CVOs¼ circumventricular organs
DGLA¼dihomo-gamma-linolenic acid
DPI¼diphenylene iodonium
Duox1¼dual oxidase1
EGF¼ epidermal growth factor
eNOS¼ endothelial nitric oxide synthase
ER¼ endoplasmic reticulum
ET-1¼ endothelin 1
H2O2¼hydrogen peroxide
HIF-1a¼hypoxia-inducible factor-1a
HO-1¼heme oxygenase-1
HUVECs¼human umbilical vein endothelial cells
ICAM-1¼ intercellular adhesion molecule 1
IL-6¼ interleukin 6
KOX¼ kidney oxidase
LDL¼ low density lipoprotein
MAP kinase¼mitogen activated protein kinase
MCP-1¼monocyte chemoattractant protein-1
MHC¼major histocompatibility complex
MMP-2¼matrix metalloproteinase 2
MMP-9¼matrix metalloproteinase 9
MPO¼myeloperoxidase
NAC¼N-acetylcysteine
NADPH¼nicotinamide adenine dinucleotide phosphate
NF-jB¼nuclear factor kappa-light-chain-enhancer
of activated B cells
NO¼nitric oxide
NoXA1¼Nox activator protein 1
NoXO1¼Nox organizer protein 1
O2
-¼ superoxide anion
PASMCs¼pulmonary artery smooth muscle cells
PDGF¼platelet-derived growth factor
PKC¼protein kinase C
PLA2¼phospholipase A2
PPARc¼peroxisome proliferator-activated receptor
gamma
RANTES¼ regulated on activation, normal T cell
expressed and secreted
ROS¼ reactive oxygen species
RVLM¼ rostral ventrolateral medulla
S17834¼ 6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy
4-methoxyphenyl)1-H benzo(b)pyran-
4-one
SFO¼ subfornical organ
SHR¼ spontaneously hypertensive rat
SMC¼ smooth muscle cell
SOD3¼ superoxide dismutase 3
STZ¼ streptozotocin
TGF-a¼ transforming growth factor a
TGF-b¼ transforming growth factor b
TNF-a¼ tumor necrosis factor-a
VCAM-1¼vascular cell adhesion molecule 1
VEGF¼vascular endothelial growth factor
VSMC¼vascular smooth muscle cell
XJP-1¼ 7,8-Dihydroxy-3-methyl-isochromanone-4
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